Orexigen Therapeutics (OREX)
Add to Watchlists Create an AlertOrexigen Therapeutics Cash and Equivalents
Orexigen Therapeutics Cash and Equivalents Chart
View Cash and Equivalents for OREX.
Start Your YCharts Pro Platinum Membership.
Orexigen Therapeutics Historical Cash and Equivalents Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | Go Pro |
| Sept. 30, 2012 | Go Pro |
| June 30, 2012 | Go Pro |
| March 31, 2012 | Go Pro |
| Dec. 31, 2011 | Go Pro |
| Sept. 30, 2011 | Go Pro |
| June 30, 2011 | Go Pro |
| March 31, 2011 | Go Pro |
| Dec. 31, 2010 | Go Pro |
| Sept. 30, 2010 | Go Pro |
| June 30, 2010 | Go Pro |
| March 31, 2010 | Go Pro |
| Dec. 31, 2009 | Go Pro |
| Sept. 30, 2009 | Go Pro |
About Cash and Equivalents
Cash and equivalents is cash or cash equivalents that a company possesses at any given time. Examples of cash equivalents are: money market accounts, treasury bills, and short term government bonds. Cash and cash equivalents are a business' most liquid assets. Cash on hand results from a positive cash flow statement.
Investors look at cash on hand as a reflection of a company's solvency and liquidity.
Learn More
View Cash and Equivalents for OREX.
Start Your YCharts Pro Platinum Membership.
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
YCharts Pro is only $199/month, and comes with a 14-day free trial.
Get Started NowAlready a YCharts Pro Platinum Member? Sign in here.
OREX Cash and Equivalents Benchmarks
| Companies | |
|---|---|
| Arena Pharmaceuticals | Go Pro |
| Vivus | Go Pro |
| Sucampo Pharmaceuticals | Go Pro |
OREX Cash and Equivalents Rankings
| Overall |
73rd percentile 2110 of 8009 |
| Sector |
74th percentile 176 of 687 in Healthcare |
| Industry |
68th percentile 22 of 69 in Drug Manufacturers - Specialty & Generic |
OREX Cash and Equivalents Range, Past 5 Years
| Minimum | Go Pro | Sep 2010 |
| Maximum | Go Pro | Dec 2011 |
| Average | Go Pro |